Malignant Gliomas Clinical Trial
Official title:
Clinical Development of MR Spectroscopy and Imaging in Brain Cancers
The Investigators will examine the disease specificity of 2-hydroxyglutarate in non-glioma brain lesions, and the clinical utility of 2-hydroxyglutarate, glycine and citrate in isocitrate dehydrogenase (IDH) mutated gliomas and IDH wild type gliomas.
2-hydroxyglutarate (2HG) imaging will identify glioma, tumor progression and response to therapy noninvasively at an earlier time point than currently detectable with standard MR imaging. This utility of 2HG can be used for improving the patient care in a more effective manner when the 2HG imaging is incorporated in regular clinical MR scans in brain tumor patients. We aim to translate the 2HG MRS protocol into two clinical MR centers at UTSouthwestern Medical Center: The Mary Nell and Ralph B. Rogers Magnetic Resonance Center with Philips 1.5Tesla and 3Tesla scanners and The Algur H. Meadows Diagnostic Imaging Center with a GE 3Tesla scanner. In addition, we will perform Magnetic Resonance (MR) scans in patients with neurological diseases that can mimic gliomas, including stroke, epilepsy, encephalitis, and brain metastases in order to establish the specificity of 2HG to malignant gliomas. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03212742 -
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01657734 -
Multimodal MR Imaging in Patients With Glioblastoma Treated With Dendritic Cell Therapy
|
N/A | |
| Completed |
NCT00165477 -
Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme
|
Phase 2 | |
| Completed |
NCT00879437 -
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
|
Phase 2 | |
| Completed |
NCT02632370 -
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
|
||
| Completed |
NCT02155452 -
Fluorescence and Glioma Heterogeneity
|
||
| Completed |
NCT00590954 -
Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas
|
Phase 2 | |
| Completed |
NCT00822887 -
Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas
|
Phase 1 | |
| Terminated |
NCT00923117 -
Sunitinib to Treat Recurrent Brain Cancer
|
Phase 2 | |
| Completed |
NCT02388659 -
Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas
|
||
| Terminated |
NCT01549392 -
Imaging Study of Glioblastomas Treated With Avastin
|
N/A | |
| Completed |
NCT00272350 -
ZD6474 to Treat Advanced Brain Cancer in Patients
|
Phase 1 | |
| Completed |
NCT00271609 -
Bevacizumab for Recurrent Malignant Glioma
|
Phase 2 | |
| Completed |
NCT00074646 -
Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas
|
Phase 1 | |
| Recruiting |
NCT01670890 -
Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas
|
Phase 2 | |
| Completed |
NCT00704080 -
A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas
|
Phase 1 | |
| Completed |
NCT00463073 -
Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas
|
Phase 2 | |
| Terminated |
NCT00671801 -
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
|
Phase 1 | |
| Withdrawn |
NCT02369367 -
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme (Phase II)
|
Phase 2 |